- Home
- PPTA vs IMCR Comparison
PPTA vs IMCR Comparison
Compare PPTA & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPTA
- IMCR
- Stock Information
- Founded
- PPTA 2011
- IMCR 2008
- Country
- PPTA United States
- IMCR United Kingdom
- Employees
- PPTA N/A
- IMCR N/A
- Industry
- PPTA Precious Metals
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPTA Basic Materials
- IMCR Health Care
- Exchange
- PPTA Nasdaq
- IMCR Nasdaq
- Market Cap
- PPTA 1.9B
- IMCR 1.8B
- IPO Year
- PPTA N/A
- IMCR 2021
- Fundamental
- Price
- PPTA $18.01
- IMCR $34.42
- Analyst Decision
- PPTA Strong Buy
- IMCR Buy
- Analyst Count
- PPTA 4
- IMCR 8
- Target Price
- PPTA $24.88
- IMCR $57.00
- AVG Volume (30 Days)
- PPTA 2.1M
- IMCR 275.9K
- Earning Date
- PPTA 11-12-2025
- IMCR 11-05-2025
- Dividend Yield
- PPTA N/A
- IMCR N/A
- EPS Growth
- PPTA N/A
- IMCR N/A
- EPS
- PPTA N/A
- IMCR N/A
- Revenue
- PPTA N/A
- IMCR $356,145,000.00
- Revenue This Year
- PPTA N/A
- IMCR $31.83
- Revenue Next Year
- PPTA N/A
- IMCR $8.50
- P/E Ratio
- PPTA N/A
- IMCR N/A
- Revenue Growth
- PPTA N/A
- IMCR 26.78
- 52 Week Low
- PPTA $7.81
- IMCR $23.15
- 52 Week High
- PPTA $19.75
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- PPTA 54.24
- IMCR 50.65
- Support Level
- PPTA $16.89
- IMCR $35.33
- Resistance Level
- PPTA $18.96
- IMCR $36.76
- Average True Range (ATR)
- PPTA 0.86
- IMCR 1.36
- MACD
- PPTA -0.19
- IMCR 0.16
- Stochastic Oscillator
- PPTA 43.04
- IMCR 40.47
About PPTA Perpetua Resources Corp.
Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.